Led · Seed · Jul 2026

Oncoliq develops a blood-based liquid-biopsy test that detects microRNAs elevated in early tumor development and uses machine-learning models to interpret results. The company reports a 90% sensitivity for its first product, Oncoliq Breast, based on its public data and already has revenue. Founded by researchers Marina Simian and Adriana de Siervi, Oncoliq plans to launch Oncoliq Mama as a Laboratory Developed Test toward the end of 2025 and to seek ANMAT approval in Argentina followed by FDA submission for the U.S. market. The startup’s strategy emphasizes a decentralized, low-cost, scalable approach to extend diagnostic access across Latin America. Its roadmap and preliminary validation underpin its current seed fundraising and positioning for future, larger clinical-stage financings.

Participated · Series A · Jan 2026

BIOMAKERS, headquartered in San Francisco, has built an integrated precision oncology ecosystem that combines large-scale molecular diagnostics, longitudinal real-world clinical data, and a deeply annotated tumor biobank. Its AI-native platform links genomic insights directly to patient samples and clinical outcomes, equipping life-science partners with intelligence to de-risk R&D, broaden trial access, and speed decision-making across the drug-development lifecycle. The company operates in more than 20 countries and runs clinical laboratories in Mexico, Brazil, and Argentina, giving it reach into diverse and under-sampled patient populations. BIOMAKERS’ tumor biobank exceeds 100,000 cases, and the firm maintains direct longitudinal connections to patients, physicians, and healthcare institutions. Having spent years assembling this infrastructure, it is now focused on scaling and monetizing the platform by deploying proprietary AI that structures and harmonizes electronic medical record data. This strategy positions BIOMAKERS as foundational infrastructure for global precision oncology R&D.

Led · Seed · Sep 2025

Cascade Bio’s core technology, branded as Body Armor for Enzymes, uses affordable, scalable materials to protect enzymes from early degradation and extend their useful lifespan from hours to months. The company deploys these fortified enzymes in cell-free systems, aiming to simplify scale-up, speed reaction rates, reduce purification steps, and lower manufacturing costs compared with microbial-host approaches. Cascade has applied its stabilization platform to more than thirty distinct enzymes and reports a consistent track record of improved durability. Early partnerships with chemical, flavor and fragrance companies, food-ingredient manufacturers, and pharmaceutical firms have demonstrated integration into existing processes and meaningful cost savings. The founding team brings expertise from Zymergen, Stanford, and the University of Colorado Boulder, supporting technical development and commercial collaboration. Headquartered in Denver with satellite teams in California and New York, Cascade plans to accelerate the transition from petrochemical processes to enzyme-driven manufacturing. Cascade Biocatalysts has developed a patent-pending Body Armor for Enzymes™ technology that improves enzyme performance and longevity to enable cost-effective, cell-free biomanufacturing. The company reports working on 15 different enzymes and achieving 100% success at improving stability under industrial conditions, including multiple paying customers at the lab scale. Initial projects target applications such as carbon dioxide capture, fragrance manufacturing, and wastewater treatment, demonstrating broad commercial potential. Cascade plans to scale its technology from the lab bench to pilot scale and support an initial wave of customers. The founders, Alex Rosay and James Weltz, combine chemical engineering backgrounds and industry experience; James invented the technology during his PhD. Headquartered in Denver, the company also has a presence in California and New York.

Participated · Series A · Jun 2024

Holoclara is a biotechnology company developing worm-derived, orally available therapeutics to treat allergic and autoimmune disorders. Its discovery engine mines immunomodulatory molecules from gut roundworms, building on research published in the Proceedings of the National Academy of Sciences. The company uses synthetic chemistry to replicate worm-derived molecules with the aim of producing safe, orally available medicines that could treat or cure prevalent diseases. Holoclara plans to progress its lead therapeutics into the clinic this year while continuing to advance its broader discovery platform to isolate additional therapeutic molecules. The company was founded and is led by physician-scientist Andrea Choe, with co-founders Paul W. Sternberg and Frank C. Schroeder, and is supported by a team of world-renowned worm biology and biotechnology experts and advisors. Holoclara positions itself as the first biotech company focused on creating safe, orally available worm-derived therapies and is backed by leading life sciences and technology investors.